Lupin gets USFDA nod for generic tablets to treat excessive daytime sleepiness
- Source
- The Economic Times - Industry
- Source link
- https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupin-gets-usfda-nod-for-generic-tablets-to-treat-excessive-daytime-sleepiness/articleshow/133290812.cms
- Published
- 2026-08-17 08:06:39
- Discovered by ProcIntel
- 2026-08-17 10:29:58
- Category
- Procurement & Supply Chain News
- Geography
- India
- Organisations
- —
- Review status
- Pending
- Record type
- REAL
Summary
Pharma major Lupin Ltd announced receiving final USFDA approval for its generic Pitolisant tablets. These tablets are indicated for treating excessive daytime sleepiness in patients. The US health regulator approved strengths of 4.45 mg and 17.8 mg. Lupin's Pitolisant tablets are bioequivalent to Wakix, a prescription medicine. This approval marks a significant step for the company in the US market.
Procurement Relevance Gate
FAIL
— score 7.0/100 — evaluated 2026-08-17 10:29:58
Only geographic exposure matched — no substantive content indicator, so this cannot pass alone.
- geographic_exposure (weight 8) — matched on "1 linked geography"
Initial Signal Assessment ProcIntel's automatic, provisional read of this individual Signal -- Initial Significance and Initial Confidence, computed deterministically before any Event extraction or human review.
A provisional, automatically-computed reading of this individual Signal, before Event extraction or human review. Not a final rating.
Not Assessed — this Signal did not pass the Procurement Relevance Gate, or is fictional/excluded test data.